Loading
Quoin Pharmaceuticals, Ltd. Stock: price and insider trades · United States
4 insiders bought €241k of shares over the last 90 days, the latest by Carter Denise P., filed 01 Sept 2026.
Quoin Pharmaceuticals, Ltd.: what insiders have been doing
Quoin Pharmaceuticals, Ltd. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 22 October 2026, brought 6 filings signed by 5 insiders.
Only purchases show up on the open market, 4 purchases in all worth €241k, filed by 4 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Myers Michael filed the largest purchase, €86k, on 1 September 2026, which represents 0.77% of the company's market value. Among those who bought: 2 senior executives, 1 finance chief and 1 chief executive.
In all, 4 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (1 September 2026) now reads 53 days. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Compared with its exchange (5,462 companies, median 28 filings), a count of 6 filings is below the norm. Over the whole record (from 2024), the tally stands at 22 purchases and 1 sale.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
25
Thresholds
n/a
Buy Volume
€1M
22 ops. · all time
Sell Volume
€200
1 ops. · all time
Who traded when
BuySaleAnthony James Culverwell2 buys
Denise P. Carter2 buys
Michael Myers2 buys
Dennis Langer1 buy
Gordon Dunn1 buy
Sally Bridget Lawlor1 buy
Since the insiders bought
- -40.9%Entry US$6.74 · Close 19 Oct 2026 US$3.98
- -40.9%Entry US$6.74 · Close 19 Oct 2026 US$3.98
- -40.9%Entry US$6.74 · Close 19 Oct 2026 US$3.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Quoin Pharmaceuticals, Ltd. Strong Buy (bullish), based on 7 analysts. Average price target: US$20.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.98
Analyst consensus
7 analystsStrong buy
US$12.00Target US$20.71(+420%)US$35.00
Income statement
EBITDA-US$16.2M
Net income-US$15.8M0.0% margin
Valuation
PER (forward)-1.2x
P/Book2.0x
Beta1.75
Balance sheet & cash
Market capUS$19.1M
Free Cash Flow-US$13.5M
Debt / Equity51%
Profitability & ownership
ROE-575.7%
ROA-114.6%
% insiders3.7%
% institutions27.8%
Last declaration on 1 September 2026
Declarations25 total
6,146 shares@ US$4.880.23% mcap12.5% of flowADSsSEC:0001104659-26-104402:0
Canonical exit: 29 Nov 2026 (T+90)
10,244 shares@ US$4.880.38% mcap100.0% of flowADSsSEC:0001104659-26-104403:0
Canonical exit: 29 Nov 2026 (T+90)
20,490 shares@ US$4.880.77% mcap26.4% of flowADSsSEC:0001104659-26-104404:0
Canonical exit: 29 Nov 2026 (T+90)
20,490 shares@ US$4.880.77% mcap26.4% of flowADSsSEC:0001104659-26-104405:0
Canonical exit: 29 Nov 2026 (T+90)
34,534 shares@ US$5.151.35% mcap57.9% of flowADSsSEC:0001104659-26-103376:0
31,352 shares@ US$5.151.23% mcap66.7% of flowADSsSEC:0001104659-26-103374:0
15,152 shares@ US$8.4942.1% of flowADSsSEC:0001104659-25-099782:0
Canonical exit: 12 Jan 2026 (T+90)
100,000 shares@ US$0.4520.8% of flowOrdinary SharesSEC:0001104659-24-132185:0
Canonical exit: 23 Mar 2025 (T+90)
122,221 shares@ US$0.4598.8% of flowOrdinary SharesSEC:0001104659-24-132187:0
Canonical exit: 23 Mar 2025 (T+90)
555,556 shares@ US$0.4573.4% of flowOrdinary SharesSEC:0001104659-24-132188:0
Canonical exit: 23 Mar 2025 (T+90)
555,556 shares@ US$0.4573.3% of flowOrdinary SharesSEC:0001104659-24-132190:0
Canonical exit: 23 Mar 2025 (T+90)
4,000 shares@ US$0.78Ordinary SharesSEC:0001104659-24-098940:1
Canonical exit: 8 Dec 2024 (T+90)
4,000 shares@ US$0.80Ordinary SharesSEC:0001104659-24-098940:2
Canonical exit: 8 Dec 2024 (T+90)
10,000 shares@ US$0.91Ordinary SharesSEC:0001104659-24-098940:3
Canonical exit: 9 Dec 2024 (T+90)
10,000 shares@ US$0.71Ordinary SharesSEC:0001104659-24-098940:4
Canonical exit: 9 Dec 2024 (T+90)
856 shares@ US$0.801.2% of flowOrdinary SharesSEC:0001104659-24-098940:0
Canonical exit: 8 Dec 2024 (T+90)
4,100 shares@ US$0.6551Ordinary SharesSEC:0001104659-24-097257:1
Canonical exit: 2 Dec 2024 (T+90)
8,825 shares@ US$0.7481Ordinary SharesSEC:0001104659-24-097257:2
Canonical exit: 3 Dec 2024 (T+90)
22,988 shares@ US$0.7965Ordinary SharesSEC:0001104659-24-097257:3
Canonical exit: 3 Dec 2024 (T+90)
5,322 shares@ US$0.6558Ordinary SharesSEC:0001104659-24-097254:1
Canonical exit: 3 Dec 2024 (T+90)
8,200 shares@ US$0.7481Ordinary SharesSEC:0001104659-24-097254:2
Canonical exit: 3 Dec 2024 (T+90)
23,572 shares@ US$0.7974Ordinary SharesSEC:0001104659-24-097254:3
Canonical exit: 3 Dec 2024 (T+90)
1,822 shares@ US$0.62530.3% of flowOrdinary SharesSEC:0001104659-24-097257:0
Canonical exit: 2 Dec 2024 (T+90)
800 shares@ US$0.6190.1% of flowOrdinary SharesSEC:0001104659-24-097254:0
Canonical exit: 2 Dec 2024 (T+90)
297 shares@ US$0.7320.1% of flowOrdinary SharesSEC:0001104659-24-070017:0
25 of 25 declarations
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd. is a pharmaceutical company focused on developing treatments for rare diseases and skin disorders. It is listed on NASDAQ under the ticker QNRX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
